Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents
- Conditions
- Obsessive Compulsive Disorder
- Interventions
- Drug: Placebo
- Registration Number
- NCT00352768
- Lead Sponsor
- Solvay Pharmaceuticals
- Brief Summary
This study is to verify the efficacy of fluvoxamine maleate given for 10 weeks in treatment of children and adolescents with obsessive-compulsive disorder
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 20
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description P Placebo - F Fluvoxamine maleate -
- Primary Outcome Measures
Name Time Method the time of onset of 25% decrease from baseline in the Japanese Version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item total score 10 weeks
- Secondary Outcome Measures
Name Time Method The Clinical Global Impression(CGI) improvement at Week 10 10 weeks
Trial Locations
- Locations (11)
S114.3.118 Hyogo Children's Hospital
🇯🇵Hyogo prefecture, Japan
S114.3.118 Hiroshima-city Funairi Hospital
🇯🇵Hiroshima prefecture, Japan
S114.3.118 Goryokai Hospital
🇯🇵Hokkaido prefecture, Japan
S114.3.118 Kyushu University Hospital
🇯🇵Fukuoka prefecture, Japan
S114.3.118 Kobe University Hospital
🇯🇵Hyogo prefecture, Japan
S114.3.118 National Hospital Organization Sakakiba
🇯🇵Mie prefecuture, Japan
S114.3.118 Tokushima University Hospital
🇯🇵Tokushima prefecture, Japan
S114.3.118 National Hospital Organization Kagawa C
🇯🇵Kagawa prefecture, Japan
S114.3.118 National Hospital Organization Kikuti N
🇯🇵Kumamoto prefecture, Japan
S114.3.118 Nara Medical University Hospital
🇯🇵Nara prefecture, Japan
S114.3.118 Kohnodai Hospital, National Center of N
🇯🇵Chiba prefecture, Japan